Incivo®(Telaprevir) data to be presented at AASLD and ISPOR on the anit-viral response, safety, tolerability and cost-effectiveness of an Incivo based regimen in the treatment of genotype-1 chronic hepatitis C
1 November 2013 | By Janssen
Janssen continues to undertake clinical studies with telaprevir to identify opportunities to serve specialized and hard-to-treat patients...